Next Article in Journal
Advances in Skin Regeneration Using Tissue Engineering
Next Article in Special Issue
SAK-HV Decreases the Self-Ubiquitination of MEKK1 to Promote Macrophage Proliferation via MAPK/ERK and JNK Pathways
Previous Article in Journal
Alleviation of Ultraviolet B-Induced Photodamage by Coffea arabica Extract in Human Skin Fibroblasts and Hairless Mouse Skin
Previous Article in Special Issue
A Review on Ubiquitination of Neurotrophin Receptors: Facts and Perspectives
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(4), 781;

The Effect of Low-Dose Proteasome Inhibition on Pre-Existing Atherosclerosis in LDL Receptor-Deficient Mice

Medizinische Klinik für Kardiologie und Angiologie, Charité–Universitätsmedizin Berlin, Campus Mitte, 10117 Berlin, Germany
Experimental and Clinical Research Center, a Joint Cooperation between the Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany
DZHK, German Center for Cardiovascular Disease, Partner Site Berlin, 10115 Berlin, Germany
Author to whom correspondence should be addressed.
Academic Editor: Nobuhiro Nakamura
Received: 19 December 2016 / Revised: 14 March 2017 / Accepted: 27 March 2017 / Published: 7 April 2017
(This article belongs to the Special Issue Ubiquitin System)
Full-Text   |   PDF [2758 KB, uploaded 7 April 2017]   |  


Dysfunction of the ubiquitin-proteasome system (UPS) has been implicated in atherosclerosis development. However, the nature of UPS dysfunction has been proposed to be specific to certain stages of atherosclerosis development, which has implications for proteasome inhibition as a potential treatment option. Recently, low-dose proteasome inhibition with bortezomib has been shown to attenuate early atherosclerosis in low-density lipoprotein receptor-deficient (LDLR−/−) mice. The present study investigates the effect of low-dose proteasome inhibition with bortezomib on pre-existing advanced atherosclerosis in LDLR−/− mice. We found that bortezomib treatment of LDLR−/− mice with pre-existing atherosclerosis does not alter lesion burden. Additionally, macrophage infiltration of aortic root plaques, total plasma cholesterol levels, and pro-inflammatory serum markers were not influenced by bortezomib. However, plaques of bortezomib-treated mice exhibited larger necrotic core areas and a significant thinning of the fibrous cap, indicating a more unstable plaque phenotype. Taking recent studies on favorable effects of proteasome inhibition in early atherogenesis into consideration, our data support the hypothesis of stage-dependent effects of proteasome inhibition in atherosclerosis. View Full-Text
Keywords: atherosclerosis; proteasome inhibition; inflammation atherosclerosis; proteasome inhibition; inflammation

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Wilck, N.; Fechner, M.; Dan, C.; Stangl, V.; Stangl, K.; Ludwig, A. The Effect of Low-Dose Proteasome Inhibition on Pre-Existing Atherosclerosis in LDL Receptor-Deficient Mice. Int. J. Mol. Sci. 2017, 18, 781.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top